Table 3.
Baseline Performance and Change in Performance for Chronic Disease Process of Care, Intermediate Outcome, and Preventive Care Measures, Stratified by Race
| Measure | Baseline performance no. satisfied/no. eligible (%) | Modeled rate of change in performance % per year (95% CI) | ||
|---|---|---|---|---|
| White | Black | White | Black | |
| Chronic disease process of care measures | ||||
| Antiplatelet drug prescribed for patients with coronary heart disease | 570/627 (90.9) | 246/293 (84.0) | ||
| Months 0–7 | 6.6 (5.0–8.2) | 17.8 (12.8–22.9) | ||
| Months 8–24 | 0.8 (0.3–1.3) | 0.3 (−1.9–2.5) | ||
| Lipid-lowering drug prescribed for patients with coronary heart disease | 582/655 (88.9) | 240/293 (81.9) | 2.8 (1.7–3.8) | 4.3 (1.5–7.0) |
| Beta-blocker prescribed for patients with a history of myocardial infarction | 98/111 (88.3) | 50/57 (87.8) | 2.4 (0.3–4.6) | 0.6 (−2.1–3.4) |
| ACEI or ARB prescribed for patients with coronary heart disease and diabetes | 137/166 (82.5) | 93/106 (87.7) | 5.8 (5.1–6.5) | 2.1 (0.4–3.9) |
| Anticoagulant prescribed for patients with heart failure and atrial fibrillation | 45/75 (60.0) | 21/32 (65.6) | 8.7 (0.6–16.7) | 9.1 (4.9–13.3) |
| ACEI or ARB prescribed for patients with heart failure with LVSD | 115/136 (84.6) | 92/109 (84.4) | 4.3 (3.8–4.9) | 1.4 (−2.9–5.6) |
| Beta-blocker prescribed for patients with heart failure with LVSD | 107/133 (80.5) | 92/109 (84.4) | 7.4 (6.2–8.5) | 4.3 (1.9–6.7) |
| Screening or treatment for diabetic nephropathy | 581/720 (80.7) | 532/628 (84.7) | 3.2 (1.5–4.9) | 1.1 (−0.3–2.5) |
| Intermediate outcome measures | ||||
| Blood pressure control for patients with hypertension | 1,433/1,722 (80.9) | 911/1,142 (79.8) | 0.9 (−0.7–2.5) | 0.9 (−1.3–3.1) |
| Glycemic control for patients with diabetes | 492/720 (68.3) | 400/628 (63.7) | 1.5 (0.5–2.6) | −0.2 (−1.0–0.7) |
| Blood pressure control for patients with diabetes | 354/528 (67.1) | 261/406 (64.3) | 2.5 (−0.4–5.4) | 1.9 (0.6–3.3) |
| LDL control for patients with diabetes | 348/628 (55.4) | 255/518 (49.2) | 3.3 (2.2–4.4) | 0.4 (−1.7–2.5) |
| Preventive care measures | ||||
| Pneumococcal immunization | 1,299/1,595 (81.8) | 504/651 (77.3) | 5.9 (4.6–7.3) | 8.4 (3.3–13.7) |
| Osteoporosis screening or treatment | 745/911 (82.0) | 375/540 (69.4) | 5.1 (4.6–5.6) | 5.5 (4.3–6.8) |
| Colorectal cancer screening | 2,373/3,552 (66.8) | 1,072/1,742 (61.5) | 3.1 (2.1–4.1) | 5.0 (3.6–6.4) |
| Cervical cancer screening | 2,571/3,094 (83.1) | 1,388/1,675 (82.9) | 2.3 (1.9–2.8) | 2.4 (1.3–3.5) |
| Breast cancer screening | 1,408/1,691 (83.3) | 851/1,093 (77.9) | −2.4 (−3.1–-1.6) | −3.3 (−4.5–-2.1) |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVSD, left ventricular systolic dysfunction; LDL, low-density lipoprotein cholesterol.